Phase 1 N=32 Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) of Alvocidib — 30; 60 mg/m2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=9 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants
Healthy Volunteers
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 6; 0; 0 Participants
Phase 1 N=28 Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets
Thrombocytopenia
Primary: Adverse Events (AEs) by Level of Severity — 8; 18; 6; 21 adverse events
Phase 1 N=6 Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
Solid Tumors
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 6; 4 Participants
Phase 1 N=50 Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults
Healthy Volunteer
Primary: Dosing Period 1: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1 — 77.4; 79.5; 256; 259 ng/mL
Phase 1 N=45 GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)
Neoplasms
Primary: Part 1: Number of Participants With Any Serious Adverse Event (SAE) and Non-serious Adverse Event (Non-SAE) — 1; 0; 3; 7 Participants
Phase 1 N=60 A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis
Osteoarthritis, Knee
Primary: SAD Part: Number of Subjects Who Experienced Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 4 Participants
Phase 1 N=12 Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
Duchenne Muscular Dystrophy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 4; 5; 3; 3 Participants
Phase 1 N=26 Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
Cancer of Kidney · Kidney Cancer · Renal Cancer
Primary: Positive Predictive Value (PPV) of 124I-cG250 Based on Positron-Emission Tomography/Computed Tomography (PET/CT) Imaging in the Detection of Clear Cell Renal Cell…
Phase 1 N=48 A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men
HIV Infections
Primary: Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs): Injection Phase — 47; 1 Participants
Phase 1 N=5 Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Solid Tumors
Primary: Number of Participants With Dose Limiting Toxicities — 0; 1; 0; 0 Participants
Phase 1 N=48 Phase I Study of OPC-61815
Congestive Heart Failure
Primary: Time-matched Difference Between the OPC-61815/Moxifloxacin and Placebo Data in Change From Baseline for QTcF in 12-lead Holter Electrocardiogram (ECG) — 0.9; 0.0; 9.9…
Phase 1 N=22 Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Neoplasms · Metastatic Cancer · Advanced Cancer
Primary: Part A: Number of Participants With Dose-limiting Toxicity (DLT) — 2; 0 Participants
Phase 1 N=24 A Safety Study of PTI-125 in Healthy Volunteers
Alzheimer Disease, Early Onset · Alzheimer Disease
Primary: Maximum Plasma Concentration (Cmax) — 315; NA; 550; NA ng/mL
Phase 1 N=26 Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell
Lymphoma, Non-Hodgkin · Lymphoma, B-Cell · Chronic Lymphocytic Leukemia
Primary: Number of Adverse Events After CAR 20/19-T Cell Infusion — 7; 4; 22 Serious Adverse Events